Department of Pharmacology, Universal College of Medical Sciences, Bhairahawa, Nepal.
Department of Pharmacology, Universal College of Medical Sciences, Bhairahawa, Nepal. Department of Quality Assurance, Biogain Remedies Pvt. Ltd., Patthardanda, Tilottama-16, Rupandehi, Nepal.
Kathmandu Univ Med J (KUMJ). 2020;18(72):367-371.
Background Off-label use means the use, concerning dosage, indication, route of administration, or age, of pharmaceutical products which are beyond the terms of the product license. For regulatory bodies and physicians, the global challenge is to achieve optimum pediatric drug therapy. Objective This prospective observational work was carried out in the paediatric department to evaluate the prescribing pattern of medicines and to identify the use of off-label drugs. Method A cross-sectional study was carried in 200 paediatric patients of ages between 0 and 12 years at the paediatric outpatient department of Universal College of Medical Sciences, Bhairahawa. Data were collected by reviewing the prescription paper and the required information was recorded using a structured data collection sheet prepared for study. The prescribing pattern was assessed by using the World Health Organization (WHO) Prescription Indicators and off-label use was assessed using the WHO Children Formulary 2010. Result Among 413 total prescriptions, only 5.56% of drugs were found to be prescribed by generic name, 16.7% of prescriptions were found to be antibiotic and 57.62% of prescribed drugs were from essential drug list. Out of 413 prescribed drugs, 16.46% of drugs were found to be off-label. The maximum extent of off-label prescribing was 51.47% in the child, followed by infants (42.6%) and neonates (5.8%). Fexofenadine; antihistaminic (23.56%), Amoxicillin+clavulanic acid; antibiotic (22.06%) had higher off-label use. Off-label dose (71.8%) was the most common cause of off-label prescribing. Conclusion Off-label prescribing among pediatric patients is common.More eminence data on the safety and efficacy of off-label medicines must be generated to rationalize paediatric pharmacotherapy.
药品标签外使用是指超出药品许可证规定的剂量、适应证、给药途径或年龄等方面使用药品。对于监管机构和医生来说,全球面临的挑战是实现最佳儿科药物治疗。
本前瞻性观察性工作在儿科病房进行,旨在评估药品的处方模式并确定标签外用药的使用情况。
在 Universal College of Medical Sciences,Bhairahawa 的儿科门诊对 0 至 12 岁的 200 名儿科患者进行了横断面研究。通过审查处方纸收集数据,并使用为研究准备的结构化数据收集表记录所需信息。使用世界卫生组织(WHO)处方指标评估处方模式,使用世界卫生组织 2010 年儿童处方集评估标签外使用。
在 413 份总处方中,仅发现 5.56%的药物按通用名开处方,16.7%的处方为抗生素,57.62%的处方药物来自基本药物清单。在 413 种开处方的药物中,发现 16.46%的药物为标签外用药。标签外用药最常见的是儿童用药(51.47%),其次是婴儿(42.6%)和新生儿(5.8%)。西替利嗪(抗组胺药)(23.56%)、阿莫西林+克拉维酸(抗生素)(22.06%)的标签外使用比例较高。标签外剂量(71.8%)是标签外用药最常见的原因。
儿科患者标签外用药很常见。必须生成更多关于标签外用药的安全性和疗效的权威数据,以合理化儿科药物治疗。